. Significance of Plasma TGF-β1 Level Detection in Patients with T2DM with Heart Failure
Plasma TGF-β1 Level
Abstract
Abstracts: Objective: To examine the significance of plasma Transforming Growth Factor-1/TGF-1 (TGF-1) level testing in patients with Type 2 Diabetes Mellitus (T2DM) and heart failure. Methods: A sample of T2DM patients who were hospitalised for dyspnea between June 2021 and June 2023 were chosen. Based on the convenience sample approach, 150 cases were screened for the study, and 50 healthy non-diabetic people without cardiac problems who completed physical examinations over the same period were included as a control group. All study participants had their serum NT-proBNP and plasma TGF-I levels checked, and the values between the two groups were compared. Then, the patients with T2DM with heart failure were grouped according to whether they were accompanied by heart failure or not and the grading of cardiac function, and then the serum NT-proBNP and plasma TGF-β1 levels were compared between the different groups of patients. The diagnostic value of plasma TGF-β1 in the occurrence of heart failure in patients with T2DM was analysed. Results: There were 54 patients without heart failure and 96 people with heart failure among the 150 T2DM patients. The cut-off point was 44.50 g/L. At this time, the sensitivity and specificity for the diagnosis of concomitant heart failure in T2DM were 79.63% and 52.51%, respectively. 96 individuals with T2DM and heart failure showed greater serum and plasma levels of NT-proBNP and TGF-1 compared to the other two groups (P 0.05). ProBNP levels and plasma TGF-1 levels had a positive and significant relationship (P 0.05). Conclusion: Plasma TGF-1 levels were much higher in T2DM patients than in the general population, and the increase in this index was more pronounced in patients who also had heart failure, which is a diagnostic indicator for T2DM and heart failure.
References
[1] Heidenreich P A , Bozkurt B , Aguilar D , et al. 2022 AHA/ ACC/ HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18):e895-1032.
[2] Groenewegen A , Rutten F H , Mosterd A , et al. Epidemiology of heart failure[J]. Eur J Heart Fail, 2020, 22(8): 1342-1356.
[3] Roger V L. Epidemiology of heart failure:a contemporary perspective[J]. Circ Res, 2021, 128(10):1421-1434.
[4] Seferovi P M , Petrie M C , Filippatos G S ,et al.Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology[J].European Journal of Heart Failure, 2018, 20(1 Suppl 1).
[5] Ritsinger V , Bodegard J , Kristofi R ,et al.History of heart failure and chronic kidney disease and the risk for all-cause death after COVID-19 during the three first waves in comparison to influenza outbreaks in Sweden[J].European Heart Journal, 2022(Supplement_2):Supplement_2.DOI:10.1093/eurheartj/ehac544.884.
[6] Seferovic P M , Petrie M C , Filippatos G S , et al. Type 2 diabetes mellitus and heart failure:a position statement from the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2018, 20(5):853-872.
[7] Su H H , Liao J M , Wang Y H ,et al.Exogenous GDF11 attenuates non-canonical TGF-β signaling to protect the heart from acute myocardial ischemia-reperfusion injury[J].Basic research in cardiology, 2019, 114(3):20-24.
[8] Sharma A , Demissei B G , Tromp J ,et al.A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure[J].European Journal of Heart Failure, 2017, 19(10):1310-1320.
[9] Hreha T N , Collins C A , Daugherty A L , et al. TGFβ1 orchestrates renal fibrosis following Escherichia coli pyelonephritis[J]. Physiol Rep, 2020, 8(6): e14401.
[10] Ambachew Y , Kahsay S , Tesfay R ,et al.Prevalence of diabetes mellitus among patients visiting medical outpatient department of Ayder referral hospital, Mekelle, Ethiopia: A three years pooled data[J].International Journal of Pharma Sciences and Research, 2021, 6(2):5.
[11] Maribel G D H , Verbrugge F H .Managing patients with chest pain at the emergency department: have high-risk heart failure phenotypes been overlooked?[J].European Heart Journal: Acute Cardiovascular Care, 2023(5):5.DOI:10.1093/ehjacc/zuad040.
[12] Castañ-Abad MT, Godoy P, Bertran S, et al. Incidence of severe exacerbation in patients diagnosed with diabetes and chronic obstructive pulmonary disease: Cohort study[ J]. Aten Primaria, 2021, 53(8): 102074.
[13] Botermann L , Wachter A , Monzel K , et al. Do patients with diabetes type 2 or chronic heart failure understand a medication plan[J]. Pharmazie, 2017, 72(12): 764-768
[14] Sacre JW, Magliano DJ, Shaw JE. Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials[ J]. Diabetes Care, 2020, 43(10): 2614-2623.
[15] LÓPEZ-DE-ANDRÉS A , DE MIGUEL-DÍEZ J , MUÑOZ-RIVAS N , et al. Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001-2015)[J]. Cardiovasc Diabetol, 2019, 18(1):60.
[16] Kpozehouen E B , Tan T , Macintyre C R .Uptake of influenza, pneumococcal and herpes zoster vaccines among people with heart failure and atrial fibrillation[J].Vaccine, 2022, 40(52):7709-7713.DOI:10.1016/j.vaccine.2022.10.090.
[17] KAPILA V , TOPF J. Sodium-glucose Co-transporter 2 inhibitor[1]associated euglycemic diabetic ketoacidosis after bariatric surgery: acase and literature review[J]. Cureus, 2021, 13(8):e17093.
[18] Marwick T H , GILLEBERT T C ,Aurigemma G ,et al. Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE)[J]. Journal of the American Society of Echocardiography, 2015, 28( 7):727-754.
[19] Del R G , Benjanuwattra J , Juarez M ,et al.Meta-Analysis Evaluating H2FPEF Score as a Prognostic Tool to Predict Mortality and Heart Failure–Related Hospitalization in Adults With Normal Left Ventricular Ejection Fraction and Dyspnea[J].The American Journal of Cardiology, 2022:173.
[20] Langogiannis N G. Transforminggrowthfactor betainmyocardialRelease [J]. NatRevCardiol, 2022, 19 (7): 435-455
[21] Lodyga M , Hinz B .TGF-β1 - A truly transforming growth factor in fibrosis and immunity[J].Seminars in cell & developmental biology, 2020, 101:123-139.
[22] Wang J Y , Gan Y B , Zhang N , et al. miR-21 overexpression enhances TGF-beta 1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy[J]. Mol Cell Endocrinol, 2014, 392(1/2): 163-172.
[23] Huynh P , Chai Z .Transforming growth factor β (TGFβ) and related molecules in chronic kidney disease (CKD)[J].Clinical Science, 2019, 133(2):287-313.
[24] Rastogi T , Ho F K , Rossignol P ,et al.Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank[J].European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology, 2022(6):24.
Copyright (c) 2024 Yunjing Sun
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.